Edition:
India

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.21USD
23 Apr 2018
Change (% chg)

$0.01 (+0.83%)
Prev Close
$1.20
Open
$1.22
Day's High
$1.26
Day's Low
$1.21
Volume
26,132
Avg. Vol
51,085
52-wk High
$2.12
52-wk Low
$1.06

Chart for

About

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its... (more)

Overall

Beta: 0.11
Market Cap(Mil.): $145.24
Shares Outstanding(Mil.): 97.47
Dividend: --
Yield (%): --

Financials

BRIEF-Pluristem Therapeutics Says Co Sold Its Entire Holdings In CHA Biotech Co For About $10.5 Mln

* PLURISTEM THERAPEUTICS - ON JAN 8, CO SOLD ITS ENTIRE HOLDINGS IN CHA BIOTECH CO LTD, CONSISTING OF 400,368 SHARES OF CHA, FOR ABOUT $10.5 MILLION

10 Jan 2018

BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia

* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​

09 Jan 2018

BRIEF-Pluristem enters agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD

* Pluristem enters into agreement with Tel Aviv Sourasky Medical Center to conduct phase i/ii trial in steroid-refractory chronic GvHD Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-PLURISTEM PRICES PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

* PLURISTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK ON THE TEL AVIV STOCK EXCHANGE

31 Oct 2017

BRIEF-Pluristem extends trial for treatment of insufficient hematopoietic recovery

* Following approval of israel’s ministry of health, Pluristem extends its trial of plx-r18 to treat insufficient Hematopoietic recovery after bone marrow transplant and opens clinical centers in Israel

26 Oct 2017

Earnings vs. Estimates